JP2015505319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505319A5 JP2015505319A5 JP2014551643A JP2014551643A JP2015505319A5 JP 2015505319 A5 JP2015505319 A5 JP 2015505319A5 JP 2014551643 A JP2014551643 A JP 2014551643A JP 2014551643 A JP2014551643 A JP 2014551643A JP 2015505319 A5 JP2015505319 A5 JP 2015505319A5
- Authority
- JP
- Japan
- Prior art keywords
- antigens
- polypeptide
- antibody
- hla
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 48
- 108091007433 antigens Proteins 0.000 claims 48
- 102000036639 antigens Human genes 0.000 claims 48
- 229920001184 polypeptide Polymers 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 239000012634 fragment Substances 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 15
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 7
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000008685 targeting Effects 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- -1 GD3 ganglioside Chemical class 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100022749 Aminopeptidase N Human genes 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 2
- 102000011899 Aquaporin 2 Human genes 0.000 claims 2
- 108010036221 Aquaporin 2 Proteins 0.000 claims 2
- 241000282836 Camelus dromedarius Species 0.000 claims 2
- 241000251730 Chondrichthyes Species 0.000 claims 2
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 108010059045 HLA-C*06 antigen Proteins 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 241000282842 Lama glama Species 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102100040120 Prominin-1 Human genes 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 102100035716 Glycophorin-A Human genes 0.000 claims 1
- 108091005250 Glycophorins Proteins 0.000 claims 1
- 108010089211 HLA-A*25 antigen Proteins 0.000 claims 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims 1
- 108010004141 HLA-B35 Antigen Proteins 0.000 claims 1
- 108010014597 HLA-B44 Antigen Proteins 0.000 claims 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims 1
- 108010039075 HLA-B8 Antigen Proteins 0.000 claims 1
- 108010070768 HLA-C*03 antigen Proteins 0.000 claims 1
- 108010069149 HLA-C*04 antigen Proteins 0.000 claims 1
- 108010007655 HLA-C*70 antigen Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100025304 Integrin beta-1 Human genes 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 claims 1
- 102000004874 Synaptophysin Human genes 0.000 claims 1
- 108090001076 Synaptophysin Proteins 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 206010054000 Type II hypersensitivity Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 102000004111 amphiphysin Human genes 0.000 claims 1
- 108090000686 amphiphysin Proteins 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000008026 type II hypersensitivity Effects 0.000 claims 1
- 230000024161 type IIb hypersensitivity Effects 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12151125.7 | 2012-01-13 | ||
| EP12151125 | 2012-01-13 | ||
| PCT/EP2013/050603 WO2013104804A2 (en) | 2012-01-13 | 2013-01-14 | Dual antigen-induced bipartite functional complementation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505319A JP2015505319A (ja) | 2015-02-19 |
| JP2015505319A5 true JP2015505319A5 (OSRAM) | 2016-03-03 |
| JP6408915B2 JP6408915B2 (ja) | 2018-10-17 |
Family
ID=47715984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551643A Active JP6408915B2 (ja) | 2012-01-13 | 2013-01-14 | 二重抗原誘導型の二部分機能相補 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20150079093A1 (OSRAM) |
| EP (3) | EP3907241A1 (OSRAM) |
| JP (1) | JP6408915B2 (OSRAM) |
| KR (2) | KR20200040893A (OSRAM) |
| CN (2) | CN108034006A (OSRAM) |
| AU (1) | AU2013208895B2 (OSRAM) |
| CA (1) | CA2861003C (OSRAM) |
| CY (1) | CY1119928T1 (OSRAM) |
| DK (1) | DK2802607T3 (OSRAM) |
| EA (1) | EA033947B1 (OSRAM) |
| ES (1) | ES2653287T3 (OSRAM) |
| HR (1) | HRP20171912T1 (OSRAM) |
| HU (1) | HUE035207T2 (OSRAM) |
| IL (1) | IL233566B (OSRAM) |
| LT (1) | LT2802607T (OSRAM) |
| MX (1) | MX359411B (OSRAM) |
| NO (1) | NO2802607T3 (OSRAM) |
| PL (1) | PL2802607T3 (OSRAM) |
| PT (1) | PT2802607T (OSRAM) |
| RS (1) | RS56773B1 (OSRAM) |
| SG (1) | SG11201403997SA (OSRAM) |
| SI (1) | SI2802607T1 (OSRAM) |
| WO (1) | WO2013104804A2 (OSRAM) |
| ZA (1) | ZA201405658B (OSRAM) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194510A1 (en) | 2011-04-22 | 2013-12-30 | Emergent Product Dev Seattle | Prostate-specific membrane antigen binding proteins and related compositionsand methods |
| JP6608282B2 (ja) | 2012-10-30 | 2019-11-20 | アラヴァックス ピーティーワイ リミテッド | 新規免疫療法用分子およびその使用 |
| RU2689552C2 (ru) | 2013-09-25 | 2019-05-28 | Аравакс Пти Лтд | Новая иммунотерапевтическая композиция и ее применения |
| CN109979526B (zh) * | 2014-03-25 | 2023-11-24 | 凡弗3基因组有限公司 | 用于功能证实癌症突变的rna分析的系统和方法 |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| US20170335009A1 (en) * | 2014-10-31 | 2017-11-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent tlr9 bispecific antibody |
| CN104592391B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
| WO2016154112A1 (en) * | 2015-03-20 | 2016-09-29 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naive t cell population |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| HRP20231134T1 (hr) | 2015-06-16 | 2024-01-05 | F. Hoffmann - La Roche Ag | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu |
| EP3112375A1 (en) * | 2015-07-03 | 2017-01-04 | Ludwig-Maximilians-Universität München | Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| EP3362929B1 (en) | 2015-10-12 | 2020-08-12 | Nantomics, LLC | Viral neoepitopes and uses thereof |
| EP3903818A1 (en) * | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| IL260937B2 (en) * | 2016-02-06 | 2024-07-01 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| WO2017189751A1 (en) | 2016-04-26 | 2017-11-02 | The University Of Utah Research Foundation | Target-binding activated split reporter systems for analyte detection and related components and methods |
| AU2017267793B2 (en) | 2016-05-20 | 2024-01-25 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| CN105920618A (zh) * | 2016-06-13 | 2016-09-07 | 上海交通大学医学院附属新华医院 | 一种生物靶向纳米基因材料及其制造方法 |
| EP3263595A1 (en) | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| EP3714944A1 (en) | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| CN108085333B (zh) * | 2016-11-14 | 2021-06-29 | 中国科学院分子植物科学卓越创新中心 | 一种延缓薯类植物生理性变质的方法 |
| US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
| KR102275008B1 (ko) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
| WO2018136725A1 (en) * | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Innate immune cell inducible binding proteins and methods of use |
| JP7556687B2 (ja) | 2017-02-24 | 2024-09-26 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| EP3600355B1 (en) * | 2017-03-28 | 2025-11-05 | The Trustees of the University of Pennsylvania | Hla-a2 specific car for use in the treatment of transplanted tissue from rejection |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| WO2019051102A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| WO2019122350A1 (en) | 2017-12-21 | 2019-06-27 | Gernot Stuhler | Specific dosage regimen for hemibody therapy |
| US12060425B2 (en) | 2018-05-03 | 2024-08-13 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| EP3796977A4 (en) * | 2018-05-17 | 2022-03-02 | The Board of Trustees of the Leland Stanford Junior University | RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT |
| WO2020010104A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Antibody tumor-targeting assembly complexes |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| EP3897851A2 (en) * | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| WO2020181140A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding proteins |
| AU2020267131A1 (en) | 2019-05-02 | 2021-11-25 | Revitope Limited | TEAC and ATTAC immunooncology compositions and methods |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| KR20220008866A (ko) | 2019-05-14 | 2022-01-21 | 하푼 테라퓨틱스, 인크. | EpCAM 결합 단백질 및 사용 방법 |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| JP7737996B2 (ja) * | 2020-01-23 | 2025-09-11 | エクスマ バイオテック コーポレイション | Ｈｅｒ２に対するキメラ抗原受容体およびその使用方法 |
| EP4097131A1 (en) * | 2020-01-29 | 2022-12-07 | Merus N.V. | Means and method for modulating immune cell engaging effects |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298921A (en) * | 2020-07-10 | 2023-02-01 | Hoffmann La Roche | Antibodies that bind to cancer cells and direct radionuclides to said cells |
| IL301276A (en) | 2020-09-24 | 2023-05-01 | Morphosys Ag | Novel human antibodies that bind to human CD3-epsilon |
| US12404315B2 (en) | 2020-12-21 | 2025-09-02 | Allogene Therapeutics, Inc. | Protease-activating CD45-gate CAR |
| JP2024504931A (ja) * | 2021-01-12 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体 |
| CN112724236B (zh) * | 2021-01-15 | 2022-03-04 | 武汉大学 | 一种两性蛋白1的抗原肽及其抗体与应用 |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| AU2022281108A1 (en) * | 2021-05-28 | 2023-12-14 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
| US20250101103A1 (en) | 2021-07-27 | 2025-03-27 | Morphosys Ag | Combinations of antigen binding molecules |
| CN113846115B (zh) * | 2021-09-24 | 2023-10-17 | 广州医科大学 | 一种屋尘螨I类变应原pro-Der p 1重组蛋白及其制备方法与应用 |
| JP2025510189A (ja) * | 2022-03-24 | 2025-04-14 | アクティニウム ファーマシューティカルズ インコーポレイテッド | ヒト化抗ｃｄ４５抗体 |
| CN114773452A (zh) * | 2022-04-21 | 2022-07-22 | 谭宏凯 | 牛乳乳清主要过敏原α-乳白蛋白的IgE结合表位 |
| US20230382960A1 (en) * | 2022-05-27 | 2023-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Truncated chlorotoxin fusion proteins and methods of use thereof |
| WO2024026317A2 (en) * | 2022-07-25 | 2024-02-01 | Vironexis Biotherapeutics Inc. | Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis |
| CN117305248A (zh) * | 2022-09-09 | 2023-12-29 | 复星凯特生物科技有限公司 | 抗EGFR和cMet双特异性嵌合抗原受体及其应用 |
| WO2024104988A1 (en) * | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with activatable effector domain |
| EP4619428A1 (en) | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Antigen binding molecules |
| EP4378529A1 (en) * | 2022-12-03 | 2024-06-05 | Universitätsklinikum Hamburg-Eppendorf | Antibody for use in a therapy involving effector cell engagement |
| WO2024208777A1 (en) * | 2023-04-03 | 2024-10-10 | F. Hoffmann-La Roche Ag | All-in-one agonistic antibodies |
| CN120917044A (zh) * | 2023-04-03 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 激动性拆分型抗体 |
| WO2024241205A1 (en) * | 2023-05-19 | 2024-11-28 | Seoul National University R&Db Foundation | Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors |
| WO2025003511A1 (en) | 2023-06-30 | 2025-01-02 | Morphosys Ag | Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025016902A1 (en) * | 2023-07-14 | 2025-01-23 | Julius-Maximilians-Universität Würzburg | Multivalent single-partite antibodies for dual-antigen restricted immunotherapy |
| WO2025036892A1 (en) | 2023-08-14 | 2025-02-20 | Morphosys Ag | Cycat halfbody molecules comprising sterically occluding moieties |
| WO2025082777A1 (en) | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ES2102007T3 (es) * | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
| GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| JP2005522514A (ja) * | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗ｈｅｒ２抗体改変体 |
| US20060252028A1 (en) | 2002-08-16 | 2006-11-09 | Hiroshi Ueda | Method of assaying interaction between proteins |
| ATE414105T1 (de) * | 2002-10-11 | 2008-11-15 | Chugai Pharmaceutical Co Ltd | Zelltod-induzierender wirkstoff |
| WO2004042404A1 (en) * | 2002-11-07 | 2004-05-21 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
| ZA200601699B (en) | 2003-10-16 | 2007-05-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
| GB0421836D0 (en) * | 2004-10-01 | 2004-11-03 | Avidex Ltd | T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents |
| JP5102772B2 (ja) * | 2005-11-29 | 2012-12-19 | ザ・ユニバーシティ・オブ・シドニー | デミボディ：二量体化活性化治療剤 |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| CN102186499B (zh) * | 2008-08-20 | 2015-05-20 | Ibc医药公司 | 用于癌症治疗的对接和锁定(dnl)疫苗 |
| GB0919751D0 (en) * | 2009-11-11 | 2009-12-30 | King S College Hospital Nhs Fo | Conjugate molecule |
| JP6040148B2 (ja) * | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
-
2013
- 2013-01-14 CN CN201711383463.0A patent/CN108034006A/zh active Pending
- 2013-01-14 KR KR1020207009766A patent/KR20200040893A/ko not_active Ceased
- 2013-01-14 EP EP21174675.5A patent/EP3907241A1/en active Pending
- 2013-01-14 US US14/371,910 patent/US20150079093A1/en not_active Abandoned
- 2013-01-14 CN CN201380012188.5A patent/CN104159923B/zh active Active
- 2013-01-14 KR KR1020147022652A patent/KR102100817B1/ko active Active
- 2013-01-14 AU AU2013208895A patent/AU2013208895B2/en active Active
- 2013-01-14 MX MX2014008468A patent/MX359411B/es active IP Right Grant
- 2013-01-14 LT LTEP13704369.1T patent/LT2802607T/lt unknown
- 2013-01-14 CA CA2861003A patent/CA2861003C/en active Active
- 2013-01-14 JP JP2014551643A patent/JP6408915B2/ja active Active
- 2013-01-14 EA EA201400811A patent/EA033947B1/ru not_active IP Right Cessation
- 2013-01-14 DK DK13704369.1T patent/DK2802607T3/en active
- 2013-01-14 ES ES13704369.1T patent/ES2653287T3/es active Active
- 2013-01-14 HU HUE13704369A patent/HUE035207T2/en unknown
- 2013-01-14 SI SI201330893T patent/SI2802607T1/en unknown
- 2013-01-14 RS RS20171357A patent/RS56773B1/sr unknown
- 2013-01-14 SG SG11201403997SA patent/SG11201403997SA/en unknown
- 2013-01-14 WO PCT/EP2013/050603 patent/WO2013104804A2/en not_active Ceased
- 2013-01-14 EP EP13704369.1A patent/EP2802607B1/en not_active Revoked
- 2013-01-14 PT PT137043691T patent/PT2802607T/pt unknown
- 2013-01-14 HR HRP20171912TT patent/HRP20171912T1/hr unknown
- 2013-01-14 EP EP17193746.9A patent/EP3333190A1/en not_active Ceased
- 2013-01-14 PL PL13704369T patent/PL2802607T3/pl unknown
- 2013-01-14 NO NO13704369A patent/NO2802607T3/no unknown
-
2014
- 2014-07-09 IL IL233566A patent/IL233566B/en active IP Right Grant
- 2014-07-30 ZA ZA2014/05658A patent/ZA201405658B/en unknown
-
2017
- 2017-12-21 CY CY20171101342T patent/CY1119928T1/el unknown
-
2019
- 2019-03-01 US US16/289,798 patent/US11427644B2/en active Active
-
2022
- 2022-06-17 US US17/842,915 patent/US20220340681A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171912T1 (hr) | Dvodjelna funkcionalna komplementacija inducirana dvojnim antigenom | |
| Friedrich et al. | Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens | |
| PH12019500603A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
| ZA202107047B (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| EA202091982A1 (ru) | Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии | |
| JP2018080171A5 (OSRAM) | ||
| EP4364809A3 (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
| TR201910814T4 (tr) | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. | |
| RU2015143207A (ru) | Композиции и способы иммунотерапии | |
| MX2020009475A (es) | Inmunoterapia con celulas car de anticuerpos biespecificos. | |
| CN109734814A (zh) | 具有免疫受体的工程化t细胞治疗癌症的用途 | |
| US10081793B2 (en) | Method for separating cells using immunorosettes and magnetic particles | |
| HRP20170658T1 (hr) | Molekula bispecifičnog protutijela | |
| JP2015502373A5 (OSRAM) | ||
| Tagawa et al. | Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma | |
| JP2017014254A5 (OSRAM) | ||
| MX2019014407A (es) | Anticuerpos terapeuticos basados en hexameros de inmunoglobulina g (igg) mutados. | |
| MX2022016300A (es) | Anticuerpo anti-trop2. | |
| ZA202209069B (en) | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| Linnebacher | Tumor-infiltrating B cells come into vogue | |
| Ju et al. | CD13+ CD4+ CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients | |
| Dao et al. | Approaching untargetable tumor-associated antigens with antibodies | |
| WO2020146706A3 (en) | Highly modular biepitopic and bispecific car-t cells for cancer immunotherapy | |
| Lin et al. | T cell modulation in immunotherapy for hematological malignancies |